雷公藤多苷增强耐顺铂人上皮性卵巢癌SKOV3/DDP细胞株顺铂敏感性的体外研究

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (12): 1364-1370.

雷公藤多苷增强耐顺铂人上皮性卵巢癌SKOV3/DDP细胞株顺铂敏感性的体外研究

刘文成¹，谭布珍¹，占欣璐¹，胡辉¹，黄根华¹，曹青²

¹南昌大学第二附属医院，妇产科，南昌 330006，江西； ²南昌大学第二附属医院，分子实验中心，南昌 330006，江西

收稿日期:2017-04-18 修回日期:2017-07-26 出版日期:2017-12-26 发布日期:2018-01-02
通讯作者: 谭布珍，通信作者，女，博士生导师，教授，研究方向：妇科肿瘤。 Tel：0791-86300502 E-mail：tanbuzhen@tom.com
作者简介:刘文成，女，硕士研究生，研究方向：妇科肿瘤。 Tel：15270804293 E-mail：liuwc2017@126.com
基金资助:
江西省自然科学基金（20161BBG70218）；江西省卫生计生委中医药管理局科研基金（2016A078）

Study on the cisplatin-sensitization effect of tripterygium glycosides on cisplatin-resistant human epithelial ovarian cancer cells (SKOV3/DDP) in vitro

LIU Wencheng ¹，TAN Buzhen ¹，ZHAN Xinlu ¹，HU Hui¹，HUANG Genhua ¹，CAO Qing ²

¹ Department of Obstetrics and Gynecology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China; ² Molecular Experiment Center, Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China

Received:2017-04-18 Revised:2017-07-26 Online:2017-12-26 Published:2018-01-02

摘要/Abstract

摘要：

目的: 探讨雷公藤多苷（GTW）对耐顺铂人上皮性卵巢癌细胞株（SKOV3/DDP）的顺铂（DDP）增敏作用及机制。方法: 将对数生长期的SKOV3/DDP细胞随机分为8组：空白对照组、10 μg/mL DDP组、50 μg/mL GTW组、800 μg/mL GTW组、3 200 μg/mL GTW组、10 μg/mL DDP+50 μg/mL GTW组、10 μg/mL DDP+800 μg/mL GTW组、10 μg/mL DDP+3 200 μg/mL GTW组，利用CCK-8法、流式细胞术、Western blot法检测各组细胞生长、细胞凋亡以及细胞谷胱甘肽S转移酶-π（GST-π）基因蛋白、P-糖蛋白（MDR1）、信号转导和转录激活因子3（STAT3）、p-STAT3的表达。结果:DDP与GTW联用在抑制SKOV3/DDP细胞生长作用上呈现相加效应；800、3 200 μg/mL GTW分别与10 μg/mL DDP联用后，可显著促进SKOV3/DDP细胞凋亡，下调p-STAT3的表达（P<0.05）。结论:GTW可显著增强SKOV3/DDP细胞对DDP的敏感性，其作用机制可能是下调STAT3信号通路中的p-STAT3表达。

关键词: 雷公藤多苷, SKOV3/DDP, 顺铂, 增敏作用, STAT3

Abstract:

AIM: To study the cisplatin-sensitization effect and mechanism of tripterygium glycosides on cisplatin-resistant human epithelial ovarian cancer cells (SKOV3/DDP). METHODS: The SKOV3/DDP cells in exponential phase of growth were randomly divided into eight groups:blank control group, 10 μg/mL DDP group, 50 μg/mL GTW group, 800 μg/mL GTW group, 3 200 μg/mL GTW group, 10 μg/mL DDP+50 μg/mL GTW group, 10 μg/mL DDP+800 μg/mL GTW group and 10 μg/mL DDP+3 200 μg/mL GTW group. Cell counting kit 8 and flow cytometry and western blot were used to detect the growth inhibiting rate and apoptosis rate and relative expression of GST-π, MDR1, STAT3, p-STAT3 of SKOV3/DDP cells of every group. RESULTS:DDP and GTW produce an additive effect when used concurrently in inhibiting growth of SKOV3/DDP cells. 800 μg/mL GTW or 3 200 μg/mL GTW combined with 10 μg/mL DDP can significantly induce apoptosis of SKOV3/DDP cells and down-regulate the expression of p-STAT3 (P<0.05). CONCLUSION: GTW can significantly enhance sensitivity of SKOV3/DDP cells to DDP. The underlying mechanism may be related with down-regulating the expression of p-STAT3 in STAT3 pathway.

Key words: tripterygium glycosides, SKOV3/DDP, cisplatin, cisplatin-sensitization effect, STAT3

中图分类号:

刘文成，谭布珍，占欣璐，胡辉，黄根华，曹青. 雷公藤多苷增强耐顺铂人上皮性卵巢癌SKOV3/DDP细胞株顺铂敏感性的体外研究[J]. 中国临床药理学与治疗学, 2017, 22(12): 1364-1370.

LIU Wencheng，TAN Buzhen，ZHAN Xinlu，HU Hui，HUANG Genhua，CAO Qing. Study on the cisplatin-sensitization effect of tripterygium glycosides on cisplatin-resistant human epithelial ovarian cancer cells (SKOV3/DDP) in vitro[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1364-1370.

参考文献

［1］Li CX, Li TS, Zhu Z, et al. Advance in studies on anti-inflammatory and immunoregulatory monomers of Tripterygium wilfordii［J］. Zhongguo Zhong Yao Za Zhi, 2014, 39(21): 4159- 4164.
［2］Wang Q, Meng J, Dong A, et al. The pharmacological effects and mechanism of tripterygium wilfordii hook F in central nervous system autoimmunity ［J］. J Altern Complement Med, 2016, 22(7): 496-502.
［3］Ma ZJ, Zhang XN, Li L, et al. Tripterygium glycosides tablet ameliorates renal tubulointerstitial fibrosis via the toll-like receptor 4/nuclear factor kappa B signaling pathway in high-fat diet fed and streptozotocin-induced diabetic rats ［J］. J Diabetes Res, 2015: 390428.
［4］Huang ZJ, Que HQ, Peng HY, et al. Reproductive toxicity of triptolide and its mechanism in male rats ［J］. Zhongguo Zhong Yao Za Zhi, 2015, 40(23): 4655-4659.
［5］Huang J, Zhang JQ, Chen Z, et al. Systematic evaluation for efficacy of tripterygium glycosides in treating diabetic nephropathy stage IV［J］. Zhongguo Zhong Yao Za Zhi, 2015, 40(15): 3100-3109.
［6］Wang HL, Jiang Q, Feng XH, et al. Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis［J］. BMC Complement Altern Med, 2016, 16: 215.
［7］Tallarida RJ. Drug synergism: its detection and applications ［J］. JPET,2001, 298: 865-872.
［8］Elvira C, Linda V, Mariangela I, et al. Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells ［J］. Mol Cancer Ther, 2004, 3: 537-544.
［9］Dimitri P, Nicolas D, Muriel G, et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models ［J］. Mol Cancer Ther, 2008, 7(7): 1836-1845.
［10］Gao Y, Rankin GO, Tu Y, et al. Theaflavin-3, 3'-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways ［J］. Int J Oncol, 2016, 48(1): 281-292.
［11］Shin K, Kim KH, Yoon MS, et al. Expression of interactive genes associated with apoptosis and their prognostic value for ovarian serous adenocarcinoma ［J］. Adv Clin Exp Med, 2016, 25(3): 513-521.
［12］Sung PL, Jan YH, Lin SC, et al. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma［J］. Oncotarget, 2016, 7(4): 4036-4047.
［13］Zhang M, Luo SC. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance［J］. Genet Mol Res, 2016, 15(1): gmr.15017496.
［14］Zhang J, Grek C, Ye ZW, et al. Pleiotropic functions of glutathione S-transferase P［J］. Adv Cancer Res, 2014, 122: 143-175.
［15］张珂, 杨兴升, 孙彩萍, 等. 谷胱甘肽转移酶π基因在COC1/DDP细胞对顺铂耐药的作用［J］. 中华外科学杂志, 2015, 32(4): 874-876.
［16］Jun Y, Peng Z, James A, et al. Advances in plant-based inhibitors of P-glycoprotein［J］. J Enzyme Inhib Med Chem, 2016, 31(6): 867-881.
［17］Chen S, Jiao JW, Sun KX, et al. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs［J］. Drug Des Devel Ther, 2015, 9: 5225-5235.
［18］Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors［J］. Biochim Biophys Acta, 2014, 1845(2): 136-154.
［19］Huang W, Dong Z, Chen Y, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo ［J］. Oncogene, 2016, 35(6): 783-792.
［20］Liu S, Sun J, Cai B, et al. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer ［J］. Tumor Biol, 2016, 37(7): 9671-9680.
［21］Park J, Park SY, Kim JH. Leukotriene B4 receptor-2 contributes to chemoresistance of SKOV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade ［J］. Biochim Biophys Acta, 2016, 1863(2): 236-243.
［22］Permuth-Wey J, Fulp WJ, Reid BM, et al. STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer ［J］. Int J Cancer, 2016, 138(3): 612-619.
［23］Tang YJ, Sun ZL, Wu WG, et al. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro［J］. Genet Mol Res, 2015, 14(1): 2450-2460.
［24］Gritsina G, Xiao F, O'Brien SW, et al. Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma growth［J］. Mol Cancer Ther, 2015, 14(4): 1035-1047.
［25］Yang Z, Liu Y, Liao J, et al. Quercetin induces endoplasmic reticulum stress to enhance cDDP cytotoxicity in ovarian cancer: involvement of STAT3 signaling ［J］. FEBS J, 2015, 282(6): 1111-1125.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	王铁烽, 苏洁, 王伟东, 夏荣双, 李思凡, 朱文瑞, 楼招欢. 三叶青调节Th17/Treg平衡抗类风湿性关节炎的作用及机制研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 138-146.
[3]	潘战和, 王馨, 苏安, 张鹏, 纪浩南, 王小梅. 基于Notch 1/NF-κB/STAT3通路探讨塞来昔布逆转NK/T细胞淋巴瘤细胞阿霉素耐药的作用机制[J]. 中国临床药理学与治疗学, 2020, 25(12): 1330-1336.
[4]	陈悦群，翟洪波，仝进毅，屈王蕾. 竹节香附素通过抑制JAK/STAT3信号转导通路抑制人子宫内膜癌HEC-1-B细胞的侵袭转移[J]. 中国临床药理学与治疗学, 2019, 24(4): 391-396.
[5]	董伟，汤喜兰，赵国巍，蒋且英，廖正根，梁新丽. 白芷香豆素类化合物对乳腺癌细胞的化疗增敏作用研究[J]. 中国临床药理学与治疗学, 2019, 24(2): 140-146.
[6]	胡炯，王伟东，王昌兴，董黎强，刘启明. 染料木素调控JAK2/STAT3信号通路改善骨性关节炎大鼠软骨代谢的作用研究[J]. 中国临床药理学与治疗学, 2018, 23(4): 383-388.
[7]	顾惠琴，赵昂，周艳芬，李静，范丽，王聪，郭素菡，王宇，张琪,马博. 基于代谢组学技术对雷公藤多苷和奥硝唑诱导大鼠弱精子症的病理机制研究[J]. 中国临床药理学与治疗学, 2017, 22(7): 721-730.
[8]	陈彬, 慕晓艳, 赵爱光, 陶丽, 徐燕. 胃肠安调控PTBP3对胃癌细胞中多基因表达的影响[J]. 中国临床药理学与治疗学, 2014, 19(5): 481-487.
[9]	慈超, 刘雯蓓, 常小丽, 何彩凤, 强娣. 扁平苔藓皮损中STAT3、VEGF、CyclinD1的表达及其相关性研究[J]. 中国临床药理学与治疗学, 2013, 18(8): 874-878.
[10]	沈水娟, 胡作祥, 王时敏, 李青华. 黄葵胶囊联合雷公藤多苷片治疗Ⅳ期糖尿病肾病的疗效观察[J]. 中国临床药理学与治疗学, 2011, 16(1): 85-88.
[11]	何军, 赵春景, 廖昌军, 杨拯, 唐樱. 番茄红素对雷公藤多苷致小鼠肝损害的保护作用[J]. 中国临床药理学与治疗学, 2010, 15(10): 1096-1099.
[12]	胡国华. 雷公藤多苷片对小儿肾性蛋白尿的影响[J]. 中国临床药理学与治疗学, 2003, 8(3): 336-338.